Predictive value of tacrolimus concentration/dose ratio in first post-transplant week for CYP3A5-polymorphism in kidney-transplant recipients

Table 2 Comparisons of tacrolimus dose, C0 and dose-adjusted C0 between CYP3A5 fast metabolizers and slow metabolizers in renal transplant recipients

Parameters	CYP3A5 fast metabolizers	CYP3A5 slow metabolizers	P value
Dose (mg/day)
Initial dose (n = 86)	5.84 ± 0.72 (5.0-8.0)	6.00 ± 0.67 (5.0-8.0)	0.192
Adjusted dose (n = 86)	6.52 ± 1.18 (5.0-10.0)	6.08 ± 0.86 (4.0-8.0)	0.149
Dose (mg/kg/day)
Initial dose (n = 86)	0.11 ± 0.01 (0.09-0.14)	0.11 ± 0.01 (0.09-0.15)	0.236
Adjusted dose (n = 86)	0.12 ± 0.02 (0.09-0.19)	0.11 ± 0.02 (0.07 ± 0.16)	0.091
Co (ng/mL)
Day 1 (n = 85)	3.93 ± 2.38 (1.1-15.1)	6.66 ± 3.25 (1.5-15.5)	< 0.001
Day 2 (n = 84)	7.46 ± 3.93 (2.5-18.7)	11.88 ± 5.45 (4.2-30.1)	< 0.001
Day 3 (n = 84)	5.84 ± 3.07 (2.0-20.4)	9.68 ± 4.37 (2.1-21.5)	< 0.001
Day 4 (n = 76)	4.66 ± 2.19 (2.2-11.1)	8.70 ± 4.56 (2.2-20.0)	< 0.001
Day 5 (n = 55)	4.10 ± 1.68 (1.9-9.5)	8.39 ± 5.17 (1.2-24.5)	< 0.001
Day 6 (n = 64)	4.38 ± 4.72 (1.5-31.0)	7.72 ± 5.03 (1.7-26.5)	< 0.001
Day 7 (n = 81)	3.11 ± 1.11 (1.1-6.3)	6.32 ± 3.08 (2.7-17.4)	< 0.001
C0/D (ng/mL)/(mg/day)
Day 1 (n = 85)	0.68 ± 0.40 (0.18-2.52)	1.11 ± 0.50 (0.21-2.21)	< 0.001
Day 2 (n = 84)	1.31 ± 0.74 (0.40-3.74)	2.00 ± 0.93 (0.61-5.02)	< 0.001
Day 3 (n = 84)	1.02 ± 0.60 (0.40-4.08)	1.63 ± 0.78 (0.34-3.66)	< 0.001
Day 4 (n = 76)	0.82 ± 0.41 (0.30-1.98)	1.48 ± 0.83 (0.31-4.00)	< 0.001
Day 5 (n = 55)	0.72 ± 0.32 (0.30-1.66)	1.45 ± 1.00 (0.17-4.90)	< 0.001
Day 6 (n = 64)	0.76 ± 0.79 (0.30-5.17)	1.32 ± 0.98 (0.24-5.30)	< 0.001
Day 7 (n = 81)	0.54 ± 0.20 (0.22-1.05)	1.07 ± 0.59 (0.48-3.48)	< 0.001

C0/D: Concentration-to-dose.